Bipolar disorder treatment for Boynton Beach — the diagnosis primary care misses.

For Boynton Beach residents in Renaissance Commons or Ocean Ridge, RECO Integrated Psychiatry is a 12-minute drive south to a psychiatrist who runs lithium at target level, titrates lamotrigine over eight weeks rather than four, and coordinates with an IPSRT-trained therapist. Bipolar depression is the diagnosis most often missed in primary care and general psychiatry — RECO's intake is built to catch it. Weekly titration visits, quarterly labs, and secure-messaging access to the prescribing clinician between visits are standard.

Boynton Beach sits seven miles north of RECO Integrated Psychiatry’s Delray Beach office along Federal Highway, a twelve-minute drive that lands residents of Renaissance Commons, Ocean Ridge, and Quantum Park inside a specialist practice before their morning coffee cools. Bipolar disorder is a condition where that proximity matters clinically — it demands repeated titrations, quarterly level draws, and monthly mood reviews that fall apart when the appointment is an hour away. RECO’s outpatient model treats bipolar I, bipolar II, and bipolar spectrum presentations without asking clients from Quantum Park or Hunters Run to uproot work, custody schedules, or family routines.

Bipolar I versus bipolar II versus bipolar spectrum

The DSM-5 distinctions are pharmacologically load-bearing, not academic. Bipolar I requires a single manic episode — at least seven days of elevated or irritable mood with grandiosity, decreased need for sleep, pressured speech, flight of ideas, or reckless behavior severe enough to impair function or require hospitalization. Bipolar II requires a hypomanic episode (four days, same symptom cluster, no functional collapse) plus a documented major depressive episode. Bipolar spectrum — BP-NOS, cyclothymia, subthreshold bipolar, antidepressant-induced hypomania — captures presentations with clear cyclicity that fail to meet full duration or severity thresholds.

The distinction changes the prescription pad. Bipolar I responds to mood stabilizers layered with second-generation antipsychotics for acute mania and maintenance. Bipolar II depression responds to lamotrigine and quetiapine but does not respond straightforwardly to lithium monotherapy the way bipolar I does. Bipolar spectrum requires antidepressants only under mood stabilizer cover, and with a low threshold to discontinue if cycling accelerates.

RECO’s diagnostic workup uses the Mood Disorder Questionnaire (MDQ), the Hypomania Checklist (HCL-32), retrospective mood charting across the last decade, and a structured hypomania history that specifically asks a collateral informant what they observed. Misdiagnosis of bipolar depression as unipolar drives most treatment failures in this population — patients are prescribed an SSRI, cycle, get labeled treatment-resistant, and stack medications for years before the underlying diagnosis is corrected.

Lithium: the treatment we take seriously when others don’t

Lithium remains the most effective long-term mood stabilizer in bipolar disorder and the only psychiatric medication with replicated evidence of an anti-suicide effect independent of mood stabilization. It is under-prescribed in general outpatient psychiatry because the monitoring feels burdensome relative to newer agents. RECO’s protocol builds the monitoring in rather than avoiding the drug.

Baseline workup includes TSH, creatinine, eGFR, calcium, CBC, and a pregnancy test where applicable. Maintenance levels target 0.6-1.0 mEq/L for bipolar I; acute mania often requires 0.8-1.2. Levels are drawn twelve hours post-dose, quarterly for the first year, then every six months once stable. Thyroid function is re-checked at six months and annually thereafter. Renal function is tracked every six to twelve months indefinitely.

Side effects that commonly end lithium trials — fine tremor, polyuria, weight gain, cognitive dulling — are usually manageable with dose reduction, timing changes, or adjunctive treatment (propranolol for tremor, amiloride for lithium-induced nephrogenic diabetes insipidus). Clinicians who abandon lithium at the first side effect are trading away the most durable long-term option in the pharmacopeia. For clients who tolerate it, the twenty-year outcome data justifies the monitoring burden.

Second-generation antipsychotics and where they fit

FDA indications in bipolar disorder are phase-specific and worth quoting precisely. Quetiapine carries indications for bipolar depression, acute mania, and maintenance. Lurasidone is approved for bipolar depression with a comparatively favorable metabolic profile. Aripiprazole is approved for acute mania and maintenance. Olanzapine covers mania and, in combination with fluoxetine, bipolar depression. Risperidone and cariprazine cover mania; cariprazine also has bipolar depression data.

Choice is driven by the pole being treated, the client’s metabolic risk, prior response history, and tolerability priorities. A patient with a family history of type 2 diabetes and an established mania history is a poor candidate for olanzapine and a reasonable candidate for aripiprazole or lurasidone. A patient with predominant depressive polarity may do better on quetiapine or lurasidone than on a mania-focused agent.

Metabolic monitoring is standard: baseline weight, waist circumference, fasting glucose or HbA1c, fasting lipid panel, and blood pressure, with repeat measurements at three months and annually thereafter. Extrapyramidal symptoms and akathisia are screened at every visit; akathisia is easily mistaken for a mixed state or agitated depression and drives non-adherence when it goes unaddressed.

Lamotrigine, valproate, and the anticonvulsant options

Lamotrigine has the strongest maintenance evidence for bipolar disorder where depression is the predominant pole and is a first-line pharmacologic option for bipolar II depression alongside quetiapine. Titration is deliberately slow — 25 mg daily for two weeks, 50 mg for two weeks, 100 mg for one week, then 200 mg — because faster titration meaningfully elevates the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis. Any rash in the first eight weeks is treated as drug-related until proven otherwise.

Valproate (divalproex) is effective for acute mania and mixed states, with target serum levels of 50-125 mcg/mL. Monitoring includes baseline and periodic LFTs, CBC with platelets, and levels drawn at steady state. Valproate is teratogenic (neural tube defects, later cognitive impact) and is not a first-line option for women of reproductive age without a documented contraception plan. Carbamazepine remains a second-line option for lithium- and valproate-refractory presentations, with attention to autoinduction, hyponatremia, and CYP450 interactions.

Each anticonvulsant has a defined monitoring cadence, and RECO runs each of them rather than defaulting to whichever agent the last prescriber started. Coordination with an evidence-based psychotherapy — interpersonal and social rhythm therapy (IPSRT), family-focused therapy, or CBT adapted for bipolar disorder — is arranged in parallel, because pharmacotherapy without rhythm stabilization and structured psychoeducation predicts relapse. Full details on RECO’s bipolar disorder treatment protocol are outlined on the service page.

What to expect on your first visit

The intake is a 60-75 minute evaluation with a board-certified psychiatrist. The clinician takes a full mood history — first episode, longitudinal course, family history to third-degree relatives, prior medication trials with doses and durations, substance use, sleep architecture, and current stressors including shift work or recent long-haul travel. Assessment scales administered typically include the MDQ, HCL-32, PHQ-9, GAD-7, and ASRS where ADHD comorbidity is suspected.

If lithium or an anticonvulsant is being considered, baseline labs are ordered the same day. A written treatment plan — pharmacology, monitoring cadence, therapy coordination, safety planning — is reviewed before the visit ends. Follow-up is typically weekly during titration, monthly once stable, and includes secure-messaging access to the prescribing clinician for urgent questions between visits.

Insurance and admissions from Boynton Beach

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Verification of benefits is typically completed within one business day, and copays, deductibles, and any prior authorization requirements — most commonly for brand lurasidone or brand lamotrigine XR — are confirmed in writing before the first appointment.

From Boynton Beach the drive is US-1 south or I-95 south to Atlantic Avenue, twelve minutes without traffic, with on-site parking. Telepsychiatry follow-ups are available once labs no longer need to be drawn in person, which covers most maintenance visits after initial stabilization.

Serving residents of: Renaissance Commons, Ocean Ridge, Quantum Park, Hunters Run, Briny Breezes.